HighTower Advisors LLC Grows Position in Cardiff Oncology, Inc. (NASDAQ:CRDF)

HighTower Advisors LLC raised its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 123.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,213 shares of the company’s stock after acquiring an additional 18,880 shares during the period. HighTower Advisors LLC owned about 0.07% of Cardiff Oncology worth $148,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of CRDF. Geode Capital Management LLC lifted its position in shares of Cardiff Oncology by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 928,232 shares of the company’s stock worth $2,479,000 after buying an additional 17,557 shares in the last quarter. State Street Corp lifted its holdings in Cardiff Oncology by 3.4% during the third quarter. State Street Corp now owns 832,652 shares of the company’s stock worth $2,223,000 after acquiring an additional 27,628 shares during the period. Bank of New York Mellon Corp boosted its position in Cardiff Oncology by 68.7% in the fourth quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company’s stock worth $1,253,000 after purchasing an additional 117,514 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Cardiff Oncology by 11.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 121,293 shares of the company’s stock worth $324,000 after purchasing an additional 12,503 shares during the last quarter. Finally, XTX Topco Ltd grew its stake in Cardiff Oncology by 44.3% in the 3rd quarter. XTX Topco Ltd now owns 120,384 shares of the company’s stock valued at $321,000 after purchasing an additional 36,947 shares during the period. 16.29% of the stock is owned by hedge funds and other institutional investors.

Cardiff Oncology Price Performance

CRDF stock opened at $2.75 on Friday. The firm has a 50 day simple moving average of $3.94 and a two-hundred day simple moving average of $3.46. The stock has a market cap of $182.94 million, a PE ratio of -2.93 and a beta of 1.74. Cardiff Oncology, Inc. has a one year low of $2.01 and a one year high of $6.35.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Piper Sandler lifted their price objective on shares of Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. HC Wainwright lifted their price target on shares of Cardiff Oncology from $13.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, February 28th.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.